Crescent Biopharma Inc (CBIO) Stock Price, Quote & News

Company Profile

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 460 5595

Website: crescentbiopharma.com

Address:

300 Fifth Avenue, Waltham, United States

FilingTracker Jul. 20 at 9:31 PM

$CBIO Large insider purchase: https://filingtracker.ai/filing/1253689/0001104659-26-085113

0 · Reply

REIoutdoorsHater Jul. 16 at 2:48 PM

$CBIO That is one hell of a dillution, and they run this up after. It’s a trap! Watch out incoming $9.00

0 · Reply

G101SPM Jul. 15 at 1:50 PM

#DILUTION Crescent Biopharma ($CBIO) prices 8.62M-share public offering at $14.50/share Penguin Solutions ($PENG) prices $650 mln 0.00% convertible notes due 2031 Q32 Bio ($QTTB) prices $200 mln public offering at $18.25/share

0 · Reply

OpenOutcrier Jul. 15 at 1:09 PM

$CBIO (-3.3% pre) Crescent Biopharma prices $125M public offering of shares and warrants https://ooc.bz/l/107887

0 · Reply

AlertsAndNews Jul. 15 at 2:35 AM

$CBIO Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants "The ordinary shares are being sold to the public at a price of $14.50 per share and the pre-funded warrants are being sold at a price to the public of $14.499 per pre-funded warrant, which represents the per ordinary share price less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Crescent from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Crescent, are expected to be approximately $125.0 million."

0 · Reply

ajmrtxl Jul. 13 at 3:03 PM

$CBIO 's latest data on SqueezeFinder

0 · Reply

ajmrtxl Jul. 2 at 4:09 PM

$CBIO 's latest data on SqueezeFinder

0 · Reply

G101SPM Jul. 2 at 12:31 PM

#DILUTION Crescent Biopharma ($CBIO) files for $500 mln mixed securities shelf offering. Eastman Kodak ($KODK) files for 4,426,268 share common stock offering by selling shareholders. QXO, Inc ($QXO) files for 19,352 share common stock offering, relates to TopBuild acquisition. Anteris Technologies Global Corp. ($AVR) files for 5,385,000 share common stock offering, relates to warrants.

1 · Reply

Merlintrader Jun. 25 at 3:07 PM

$PALI Russell 2026 Biotech Watchlist: $CNTX $IMMX $CBIO and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/

0 · Reply

ProfProfit Jun. 23 at 8:06 PM

$CBIO 🤦‍♂️

0 · Reply

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

2026-07-15T02:15:08.000Z - 6 days ago

Crescent Biopharma 8.095M share Spot Secondary priced at $14.50

Jul 14, 2026, 9:45 PM EDT - 6 days ago

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

2026-07-14T20:25:22.000Z - 6 days ago

Crescent Biopharma files ordinary shares offering, no amount given

Jul 14, 2026, 4:01 PM EDT - 6 days ago

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Jul 1, 2026, 8:00 AM EDT - 20 days ago

Crescent Biopharma Registration statement: Registration filing

Jun 26, 2026, 4:15 PM EDT - 24 days ago

Crescent Biopharma Announces Grants of Inducement Awards

Jun 8, 2026, 8:40 AM EDT - 6 weeks ago

Crescent Biopharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 6 weeks ago

Crescent Biopharma Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 4:15 PM EDT - 6 weeks ago

Crescent Biopharma to Present at June Investor Conferences

Jun 2, 2026, 9:00 AM EDT - 7 weeks ago

Crescent Biopharma Transcript: AGM 2026

2026-06-01T10:31:19.000Z - 7 weeks ago

Crescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright

May 26, 2026, 11:30 AM EDT - 2 months ago

Crescent Biopharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 21, 2026, 5:30 PM EDT - 2 months ago

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

May 20, 2026, 2:30 PM EDT - 2 months ago

Crescent Biopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 13, 2026, 7:20 PM EDT - 2 months ago

Crescent Biopharma Transcript: Bank of America Global Healthcare Conference 2026

May 6, 2026, 7:30 AM EDT - 2 months ago

Crescent Biopharma to Present at May Investor Conferences

2026-04-29T21:25:20.000Z - 2 months ago

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)

Apr 29, 2026, 4:15 PM EDT - 2 months ago

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Crescent Biopharma Quarterly report: Q1 2026

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Crescent Biopharma Earnings release: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Crescent Biopharma Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Crescent Biopharma Proxy statement: Proxy filing

2026-04-08T20:50:50.000Z - 3 months ago

Crescent Biopharma management to meet with Cantor Fitzgerald

Mar 11, 2026, 8:40 AM EDT - 4 months ago

Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 3:50 PM EST - 5 months ago

Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-02T11:44:56.000Z - 5 months ago

Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright

2026-02-26T12:49:35.000Z - 5 months ago

Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year

2026-02-26T12:48:53.000Z - 5 months ago

Crescent Biopharma sees cash runway into 2028

Feb 26, 2026, 7:30 AM EST - 5 months ago

Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 26, 2026, 7:30 AM EST - 5 months ago

Crescent Biopharma Annual report: Q4 2025

Feb 26, 2026, 7:30 AM EST - 5 months ago

Crescent Biopharma Earnings release: Q4 2025

Feb 23, 2026, 7:30 AM EST - 5 months ago

Crescent Biopharma to Present at March Investor Conferences

2026-02-18T12:36:19.000Z - 5 months ago

Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial

Feb 18, 2026, 7:30 AM EST - 5 months ago

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

Feb 12, 2026, 11:30 AM EST - 5 months ago

Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:30 AM EST - 5 months ago

Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-28T11:36:53.000Z - 6 months ago

Crescent Biopharma initiated with an Overweight at Piper Sandler

2026-01-21T11:35:26.000Z - 6 months ago

Crescent Biopharma initiated with a Buy at Guggenheim

SMMT

2026-01-07T22:15:16.000Z - 6 months ago

Crescent Biopharma files to sell 19.71M shares of common stock for holders

2026-01-05T12:16:19.000Z - 7 months ago

Crescent Biopharma announces regulatory clearance of IND applications

Jan 5, 2026, 7:00 AM EST - 7 months ago

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors

2025-12-04T20:35:38.000Z - 8 months ago

Crescent Biopharma price target raised to $32 from $28 at Stifel

2025-12-04T13:54:36.000Z - 8 months ago

Why Is Crescent Biopharma Stock (CBIO) Up Today?

Dec 4, 2025, 8:00 AM EST - 8 months ago

Crescent Biopharma Transcript: Partnership

Dec 4, 2025, 8:00 AM EST - 8 months ago

Crescent Biopharma Press release: Partnership

Dec 4, 2025, 8:00 AM EST - 8 months ago

Crescent Biopharma Slides: Partnership

Dec 4, 2025, 6:35 AM EST - 8 months ago

Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors

Dec 4, 2025, 6:30 AM EST - 8 months ago

Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics

Nov 19, 2025, 4:30 AM EST - 8 months ago

Crescent Biopharma Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 8 months ago

Crescent Biopharma Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 8:00 AM EST - 9 months ago

Crescent Biopharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:30 AM EST - 9 months ago

Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 9 months ago

Crescent Biopharma Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Crescent Biopharma Earnings release: Q3 2025

Nov 5, 2025, 7:30 AM EST - 9 months ago

Crescent Biopharma to Present at November Investor Conferences

Nov 4, 2025, 6:00 PM EST - 9 months ago

Crescent Biopharma Slides: Corporate Presentation

Nov 4, 2025, 9:05 AM EST - 9 months ago

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 8, 2025, 5:35 PM EDT - 11 months ago

Crescent Biopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 1:00 PM EDT - 11 months ago

Crescent Biopharma Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 6:00 PM EDT - 11 months ago

Crescent Biopharma Slides: Corporate Presentation

Aug 28, 2025, 7:30 AM EDT - 11 months ago

Crescent Biopharma to Present at September Investor Conferences

Jul 31, 2025, 7:34 AM EDT - 1 year ago

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Earnings release: Q2 2025

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Quarterly report: Q2 2025

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Slides: Corporate Presentation

Jun 16, 2025, 7:00 AM EDT - 1 year ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 5, 2025, 4:01 PM EDT - 1 year ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

May 29, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 16, 2025, 1:55 PM EDT - 1 year ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Mar 5, 2025, 11:20 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Feb 26, 2025, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Oct 29, 2024, 11:47 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

Oct 29, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 6:30 AM EDT - 1 year ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Jul 25, 2024, 9:00 AM EDT - 2 years ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

$GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

Jun 4, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

$GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024$

May 29, 2024, 4:01 PM EDT - 2 years ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

$GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)$

May 6, 2024, 6:00 AM EDT - 2 years ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Apr 25, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Mar 27, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Feb 26, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 12, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2024, 7:00 AM EST - 2 years ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Dec 10, 2023, 12:00 PM EST - 2 years ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Nov 9, 2023, 7:00 AM EST - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 3, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Oct 30, 2023, 12:00 PM EDT - 2 years ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

FilingTracker Jul. 20 at 9:31 PM

$CBIO Large insider purchase: https://filingtracker.ai/filing/1253689/0001104659-26-085113

0 · Reply

REIoutdoorsHater Jul. 16 at 2:48 PM

$CBIO That is one hell of a dillution, and they run this up after. It’s a trap! Watch out incoming $9.00

0 · Reply

G101SPM Jul. 15 at 1:50 PM

0 · Reply

OpenOutcrier Jul. 15 at 1:09 PM

$CBIO (-3.3% pre) Crescent Biopharma prices $125M public offering of shares and warrants https://ooc.bz/l/107887

0 · Reply

AlertsAndNews Jul. 15 at 2:35 AM

0 · Reply

ajmrtxl Jul. 13 at 3:03 PM

$CBIO 's latest data on SqueezeFinder

0 · Reply

ajmrtxl Jul. 2 at 4:09 PM

$CBIO 's latest data on SqueezeFinder

0 · Reply

G101SPM Jul. 2 at 12:31 PM

1 · Reply

Merlintrader Jun. 25 at 3:07 PM

$PALI Russell 2026 Biotech Watchlist: $CNTX $IMMX $CBIO and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/

0 · Reply

ProfProfit Jun. 23 at 8:06 PM

$CBIO 🤦‍♂️

0 · Reply

outlawinvestor1 Jun. 19 at 9:59 PM

$APGE 💥🥳 $SYRE $ORKA $JBIO $CBIO https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-nears-11-billion-deal-apogee-therapeutics-ft-reports-2026-06-19/

0 · Reply

MorenitaScorp Jun. 8 at 1:58 AM

$CBIO ⌚️

0 · Reply

focafoca99 Jun. 3 at 1:26 PM

$CBIO recorded its annual meeting voting results, electing two Class II directors and approving key shareholder proposals.

0 · Reply

focafoca99 May. 22 at 12:14 AM

$CBIO previewed its ASCEND trial poster for the ASCO 2026 meeting.

0 · Reply

outlawinvestor1 May. 16 at 10:04 AM

updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO

1 · Reply

ProfProfit May. 15 at 12:07 AM

$CBIO why the f did I not buy more at $17 a few days ago??? 🤬

0 · Reply

NVDAMillionaire May. 13 at 6:04 PM

$CBIO Excellent article that nails exactly where CBIO stands right now. So if you want to update your CBIO knowledge or get acquainted with CBIO, this is a must read. https://everyticker.com/quote/CBIO/analysis/crescent-biopharma-s-189m-clinical-reset-three-shots-at-a-13b-valuation-nasdaq-cbio

0 · Reply

MorenitaScorp May. 5 at 2:18 PM

$CBIO ⌚️

0 · Reply

PenkeInvesting May. 4 at 4:20 PM

Fundamental analysis of $CBIO (CRESCENT BIOPHARMA, INC.) based on financial data and reported results. #CBIO

0 · Reply

lyonsa14 May. 1 at 5:56 PM

$CBIO Looks like it’s falling in sympathy with Summit Therapeutics. https://www.fiercepharma.com/pharma/summit-pd-1vegf-interim-trial-miss-surprises-analysts-shares-tumble

0 · Reply

ProfProfit May. 1 at 3:44 PM

$CBIO why the 30% drop today?

0 · Reply

Market Cap	406.47M
Revenue (ttm)	10.84M
Net Income (ttm)	-153.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,420.11%
Debt to Equity Ratio	0.00

Volume	456,708
Avg Vol	349,628
Day's Range	N/A - N/A
Shares Out	27.56M
Stochastic %K	18%
Beta	1.20
Analysts	Strong Sell
Price Target	$31.67